Literature DB >> 28807360

Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET).

K Harrington1, E Hall1, M Hawkins2, A Henry3, R MacKay4, T Maughan5, A McDonald1, C Nutting6, U Oelfke1, D Sebag-Montefiore3, R A Sharma7, M van Herk8, C Faivre-Finn9.   

Abstract

Entities:  

Year:  2017        PMID： 28807360      PMCID： PMC6155492          DOI： 10.1016/j.clon.2017.07.016

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  12 in total

1.  Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy.

Authors:  Ellen Donovan; Natalie Bleakley; Erica Denholm; Phil Evans; Lone Gothard; Jane Hanson; Clare Peckitt; Stephanie Reise; Gill Ross; Grace Sharp; Richard Symonds-Tayler; Diana Tait; John Yarnold
Journal:  Radiother Oncol       Date:  2007-01-16       Impact factor: 6.280

2.  Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.

Authors:  Achilles J Fakiris; Ronald C McGarry; Constantin T Yiannoutsos; Lech Papiez; Mark Williams; Mark A Henderson; Robert Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-27       Impact factor: 7.038

3.  MR guidance in radiotherapy.

Authors:  Jan J W Lagendijk; Bas W Raaymakers; Cornelis A T Van den Berg; Marinus A Moerland; Marielle E Philippens; Marco van Vulpen
Journal:  Phys Med Biol       Date:  2014-10-16       Impact factor: 3.609

4.  Dose escalation in lung cancer: have we gone full circle?

Authors:  Corinne Faivre-Finn
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

Review 5.  Advances in radiotherapy.

Authors:  Saif S Ahmad; Simon Duke; Rajesh Jena; Michael V Williams; Neil G Burnet
Journal:  BMJ       Date:  2012-12-04

Review 6.  Stereotactic body radiotherapy for oligometastases.

Authors:  Alison C Tree; Vincent S Khoo; Rosalind A Eeles; Merina Ahmed; David P Dearnaley; Maria A Hawkins; Robert A Huddart; Christopher M Nutting; Peter J Ostler; Nicholas J van As
Journal:  Lancet Oncol       Date:  2013-01       Impact factor: 41.316

7.  Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

Authors:  Christopher M Nutting; James P Morden; Kevin J Harrington; Teresa Guerrero Urbano; Shreerang A Bhide; Catharine Clark; Elizabeth A Miles; Aisha B Miah; Kate Newbold; MaryAnne Tanay; Fawzi Adab; Sarah J Jefferies; Christopher Scrase; Beng K Yap; Roger P A'Hern; Mark A Sydenham; Marie Emson; Emma Hall
Journal:  Lancet Oncol       Date:  2011-01-12       Impact factor: 41.316

8.  Hypofractionation in clinical trials for prostate cancer.

Authors:  P J Hoskin; D P Dearnaley
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-04-24       Impact factor: 4.126

9.  The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

Authors:  Joanne S Haviland; J Roger Owen; John A Dewar; Rajiv K Agrawal; Jane Barrett; Peter J Barrett-Lee; H Jane Dobbs; Penelope Hopwood; Pat A Lawton; Brian J Magee; Judith Mills; Sandra Simmons; Mark A Sydenham; Karen Venables; Judith M Bliss; John R Yarnold
Journal:  Lancet Oncol       Date:  2013-09-19       Impact factor: 41.316

10.  Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Authors:  Anna Wilkins; Helen Mossop; Isabel Syndikus; Vincent Khoo; David Bloomfield; Chris Parker; John Logue; Christopher Scrase; Helen Patterson; Alison Birtle; John Staffurth; Zafar Malik; Miguel Panades; Chinnamani Eswar; John Graham; Martin Russell; Peter Kirkbride; Joe M O'Sullivan; Annie Gao; Clare Cruickshank; Clare Griffin; David Dearnaley; Emma Hall
Journal:  Lancet Oncol       Date:  2015-10-28       Impact factor: 41.316
View more
  2 in total

1.  Added value of diffusion-weighted MRI for nodal radiotherapy planning in pelvic malignancies.

Authors:  N Sushentsev; H Martin; Y Rimmer; T Barrett
Journal:  Clin Transl Oncol       Date:  2019-03-13       Impact factor: 3.405

2.  The advanced radiotherapy network (ART-NET) UK lung stereotactic ablative radiotherapy survey: national provision and a focus on image guidance.

Authors:  Matthew Beasley; Sean Brown; Helen McNair; Corinne Faivre-Finn; Kevin Franks; Louise Murray; Marcel van Herk; Ann Henry
Journal:  Br J Radiol       Date:  2019-04-24       Impact factor: 3.039
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.